NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

ONO-4059 Study in Patients With Steroid-resistant Pemphigus

Active Not RecruitingPhase 3

Sponsor: Ono Pharmaceutical Co., Ltd.

Conditions: Pemphigus, Steroid-resistant Pemphigus

Interventions: ONO-4059, ONO-4059 placebo

Countries: Japan

ONO-4059-10:Multicenter, placebo-controlled, randomized, double-blind, Phase 3 study in patients with steroid-resistant pemphigus

Eligibility overview

Sex: ALL

Age: 20 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with a diagnosis of pemphigus
* Patients with a re-increase in the pemphigus disease area index (PDAI) score before oral corticosteroid tapering to 10mg/day of prednisolone (PSL) equivalent

Exclusion Criteria:

* Patients with an active infection
* Patients with malignancy
* Patients with past history of serious allergy or anaphylaxis

Locations (25)

Aichi, Japan
Aichi, Japan
Ehime, Japan
Fukuoka, Japan
Fukushima, Japan
Gunma, Japan
Hokkaido, Japan
Kagoshima, Japan
Kanagawa, Japan
Kanagawa, Japan
Kanagawa, Japan
Kumamoto, Japan
Kyoto, Japan
Niigata, Japan
Okayama, Japan
Okinawa, Japan
Osaka, Japan
Osaka, Japan
Saitama, Japan
Shiga, Japan
Tochigi, Japan
Tokyo, Japan
Tokyo, Japan
Tokyo, Japan
Yamagata, Japan